MedTrace Logo

Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies

NCT07504263 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-03-31

No results posted yet for this study

Summary

Phase 1/2a Study of RP-001 in participants with Advanced Malignancies

Conditions

Interventions

DRUG

RP-001

A new class of Taxane.

Sponsors & Collaborators

  • Recurv Pharma Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-23
Primary Completion
2027-12-01
Completion
2028-04-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07504263 on ClinicalTrials.gov